MedTrace Logo

Characterization of Signs and Symptoms of Participants With and Without Meibomian Gland Dysfunction

NCT01979887 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 75

Last updated 2014-08-15

No results posted yet for this study

Summary

This is an exploratory study to evaluate endpoints used to characterize participants with and without meibomian gland dysfunction (MGD) and will evaluate the correlation between signs and symptoms of MGD. No investigational drug will be administered in this study.

Conditions

  • Meibomian Glands

Interventions

PROCEDURE

Meibum Expression

Meibum expression as per protocol. No investigational drug is administered in this study.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Medical Director · Allergan

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2014-07-31
Completion
2014-07-31

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01979887 on ClinicalTrials.gov